Literature DB >> 11373296

Identification of phosphorylation sites for Bruton's tyrosine kinase within the transcriptional regulator BAP/TFII-I.

A M Egloff1, S Desiderio.   

Abstract

Bruton's tyrosine kinase (Btk), a member of the Tec family of cytosolic kinases, is essential for B cell development and function. BAP/TFII-I, a protein implicated in transcriptional regulation, is associated with Btk in B cells and is transiently phosphorylated on tyrosine following B cell receptor engagement. BAP/TFII-I is a substrate for Btk in vitro and is hyperphosphorylated on tyrosine upon coexpression with Btk in mammalian cells. In an effort to understand the physiologic consequences of BAP/TFII-I tyrosine phosphorylation following B cell receptor stimulation, site-directed mutagenesis and phosphopeptide mapping were used to locate the predominant sites of BAP/TFII-I phosphorylation by Btk in vitro. These residues, Tyr248, Tyr357, and Tyr462, were also found to be the major sites for Btk-dependent phosphorylation of BAP/TFII-I in vivo. Residues Tyr357 and Tyr462 are contained within the loop regions of adjacent helix-loop-helix-like repeats within BAP/TFII-I. Mutation of either Tyr248, Tyr357, or Tyr462 to phenylalanine reduced transcription from a c-fos promoter relative to wild-type BAP/TFII-I in transfected COS-7 cells, consistent with the interpretation that phosphorylation at these sites contributes to transcriptional activation. Phosphorylation of BAP/TFII-I by Btk may link engagement of receptors such as surface immunoglobulin to modulation of gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11373296     DOI: 10.1074/jbc.M103692200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

2.  Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I.

Authors:  Jaya Rajaiya; Jamee C Nixon; Neil Ayers; Zana P Desgranges; Ananda L Roy; Carol F Webb
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 3.  Biochemistry and biology of the inducible multifunctional transcription factor TFII-I: 10 years later.

Authors:  Ananda L Roy
Journal:  Gene       Date:  2011-10-21       Impact factor: 3.688

4.  Phosphoproteome profiling of transforming growth factor (TGF)-beta signaling: abrogation of TGFbeta1-dependent phosphorylation of transcription factor-II-I (TFII-I) enhances cooperation of TFII-I and Smad3 in transcription.

Authors:  Taras Stasyk; Anna Dubrovska; Marta Lomnytska; Ihor Yakymovych; Christer Wernstedt; Carl-Henrik Heldin; Ulf Hellman; Serhiy Souchelnytskyi
Journal:  Mol Biol Cell       Date:  2005-07-29       Impact factor: 4.138

5.  Characterization of a novel interaction between transcription factor TFII-I and the inducible tyrosine kinase in T cells.

Authors:  Catarina Sacristán; Stefan A Schattgen; Leslie J Berg; Stephen C Bunnell; Ananda L Roy; Yvonne Rosenstein
Journal:  Eur J Immunol       Date:  2009-09       Impact factor: 5.532

6.  Disruption of Src Is Associated with Phenotypes Related to Williams-Beuren Syndrome and Altered Cellular Localization of TFII-I

Authors:  Laleh Sinai; Evgueni A Ivakine; Emily Lam; Marielle Deurloo; Joana Dida; Ralph A Zirngibl; Cynthia Jung; Jane E Aubin; Zhong-Ping Feng; John Yeomans; Roderick R McInnes; Lucy R Osborne; John C Roder
Journal:  eNeuro       Date:  2015-03-30

7.  Dermatan Sulfate Is a Potential Regulator of IgH via Interactions With Pre-BCR, GTF2I, and BiP ER Complex in Pre-B Lymphoblasts.

Authors:  Jongmin Lee; Jung-Hyun Rho; Michael H Roehrl; Julia Y Wang
Journal:  Front Immunol       Date:  2021-05-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.